Existing networks

Existing Networks or registries and biobanks

  • The SWEET group

    SWEET e.V. is an international network of Centers of Reference for pediatric diabetes care with the aim of improving secondary prevention, diagnosis and control of type 1 and type 2 diabetes in children and adolescents. Initiated with support of the EU Public Health Program in 2008 the SWEET group has over 9 years of experience in creating and sustaining a high quality professional network based on agreed standards of care, criteria for certification, international guidelines and quality control, including peer review and data collection, sharing and benchmarking. In the meantime, SWEET is organized as a registered charity with close ties to scientific organizations such as the International Society for Pediatric and Adolescent Diabetes (ISPAD) and NGO’s such as IDF Europe.

    visit website

  • EURO-WABB

    The EURO-WABB Project is a collaboration of doctors, scientists and patient support groups from all over Europe. Within the EU Health Programme 2008-2013 and its call for promoting health through the creation of new registers for rare diseases, EURO-WABB is supported by The EU Directorate General for Health and Consumers (DG-SANCO) via its Executive Agency for Health and Consumers. The overall aim is for this register to be a key instrument to increase knowledge on these rare diseases, improve the lives of affected people through better management, and to develop clinical research.

    visit website

  • Diabetes genes

    Diabetesgenes.org aims to provide information for patients and professionals on research and clinical care in genetic types of diabetes. This website is run by the Diabetes Research department and the Centre for Molecular Genetics at the University of Exeter Medical School and Royal Devon and Exeter Hospital, Exeter, UK.

    visit website

  • Innovative medicines initiative

    The Innovative Medicines Initiative (IMI) is Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
    It contains information on several projects related to glucose & insulin homeostasis:

  • DIRECT: Diabetes research on patient stratification
  • IMIDIA: Improving beta-cell function and identification of diagnostic biomarkers For treatment monitoring in diabetes
  • INNODIA: Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes
  • RHAPSODY: Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification
  • SUMMIT: Surrogate markers for micro- and macro-vascular hard endpoints for innovative diabetes tools
  • visit website